Article

Neuropeptide could have role in retinal trauma

In studies that could have bearing on the treatment of soldiers and others who experience trauma to the retina or central nervous system, Joan Stein-Streilein, PhD, has hypothesized that the receptor antagonist of Substance P, a neuroinflammatory peptide, may have a therapeutic role.

Fort Lauderdale, FL-In studies that could have bearing on the treatment of soldiers and others who experience trauma to the retina or central nervous system, Joan Stein-Streilein, PhD, has hypothesized that the receptor antagonist of Substance P, a neuroinflammatory peptide, may have a therapeutic role.

Dr. Stein-Streilein is senior scientist and Margaret S. Sinon Scholar in Ocular and Neurological Inflammation Research at the Schepens Eye Research Institute, Massachusetts Eye and Ear Center, Boston. Using a retinal laser burn (RLB) model in mice to study what happens to immune regulation in an injured retina, Dr. Stein-Streilein found that RLB induces extended bilateral loss of anterior chamber associated immune deviation (ACAID). In one study, immune regulation was not restored in either the burned or contralateral eye 77 days after trauma.

To determine why the contralateral eye lost the immune privilege, she conducted further studies to see if injuries more distant in the central nervous system also mitigated regulation in the eye. As in the earlier studies, both eyes were affected and had not regained immune regulation by 21 days. Similar results were found in studies of traumatic brain injury.

As they investigated the reason for the loss of immune privilege, Dr. Stein-Streilein and colleagues suspected that Substance P was involved in a change of neuronal signals and looked for evidence in its receptor, NKR-1. After corroborating this idea, the team tested a receptor antagonist, Spantide I, and found that it restored the ability to induce ACAID, but only very early after it was injected into the anterior chamber.

These studies seem to confirm that Substance P plays a role in optic nerve crush and exaggerates the immune response, allowing inflammation post-injury, Dr. Stein-Streilein said. The early findings suggest that it is also possible that a Substance P receptor antagonist could be used as part of novel therapy for ocular or central nervous system trauma.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.